Antibody-drug conjugates in lung cancer: dawn of a new era?

Niamh Coleman(The University of Texas MD Anderson Cancer Center), Xiuning Le(The University of Texas MD Anderson Cancer Center)

npj Precision Oncology

January 11, 2023

10.1038/s41698-022-00338-9

Cited by 116

Related Papers

AI in drug discovery and its clinical relevance

|Heliyon|2023|271

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

|The Lancet Digital Health|2023|108

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

|Clinical Cancer Research|2025|6